Merck & Co., (MRK) and Daiichi Sankyo Announces Positive Results for Ifinatamab deruxtecan

Merck & Co., Inc. (NYSE:MRK) is one of the Blue Chip Stocks to Buy with the Lowest PE Ratios. On September 7, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced positive Phase 2 results for Ifinatamab deruxtecan in treating extensive-stage small cell lung cancer.

The trial showed a confirmed objective response rate of 48.2% in 137 previously treated ES-SCLC patients. Management noted that 3 complete responses, 63 partial responses, and 54 cases of stable disease were seen. Moreover, the disease control rate was 87.6% with a median duration of response being 5.3 months and a median overall survival of 10.3 months.

The drug under trial is a potential first-in-class B7-H3-directed antibody-drug conjugate, which is being jointly developed by Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo. ES-SCLC is an aggressive cancer with a poor prognosis and limited treatment options after chemotherapy.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on developing and delivering prescription medicines, vaccines, and animal health products.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.